ArticleIDCases2026
Ocular mpox presenting as sclerokeratouveitis: A case report.
Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To describe a case of mpox-associated ocular disease in an HIV-infected patient. Case report: A 50-year-old man presented with severe ocular inflammation including corneal ulceration, scleral involvement and anterior uveitis. Mpox infection was confirmed by PCR from ocular, pharyngeal, and cutaneous samples, with ocular positivity persisting the longest. Initial treatment with a subtherapeutic self-administered dose of tecovirimat failed to control inflammation. Clinical improvement was achieved after increasing the tecovirimat dose and introducing topical corticosteroids. Despite visual acuity recovery, permanent corneal damage remained. Conclusions and Importance: This case highlights the importance of maintaining a high index of suspicion for ocular mpox. Although tecovirimat remains a compassionate-use therapy, it has demonstrated effectiveness in managing ocular manifestations. However, optimal dosing and treatment duration-particularly in cases with persistent inflammation or recurrence-are not yet well established. Our experience supports the short-term use of topical corticosteroids in combination with systemic antivirals, under close monitoring. Long-term follow-up is essential to assess recurrence, viral persistence, and late complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.